Department of Clinical Pharmacology, Division of Pathological Sciences, Kyoto Pharmaceutical University, Kyoto, Japan.
Mississippi Center for Heart Research, Department of Physiology and Biophysics, University of Mississippi Medical Center, and Research Service, G.V. (Sonny) Montgomery Veterans Affairs Medical Center, Jackson, MS, USA.
Pharmacol Ther. 2019 Jan;193:99-120. doi: 10.1016/j.pharmthera.2018.08.014. Epub 2018 Aug 25.
Whereas hypertension, diabetes, and dyslipidemia are age-related risk factors for cardiovascular disease (CVD) and chronic kidney disease (CKD), aging alone is an independent risk factor. With advancing age, the heart and kidney gradually but significantly undergo inflammation and subsequent fibrosis, which eventually results in an irreversible decline in organ physiology. Through cardiorenal network interactions, cardiac dysfunction leads to and responds to renal injury, and both facilitate aging effects. Thus, a comprehensive strategy is needed to evaluate the cardiorenal aging network. Common hallmarks shared across systems include extracellular matrix (ECM) accumulation, along with upregulation of matrix metalloproteinases (MMPs) including MMP-9. The wide range of MMP-9 substrates, including ECM components and inflammatory cytokines, implicates MMP-9 in a variety of pathological and age-related processes. In particular, there is strong evidence that inflammatory cell-derived MMP-9 exacerbates cardiorenal aging. This review explores the potential therapeutic targets against CVD and CKD in the elderly, focusing on ECM and MMP roles.
虽然高血压、糖尿病和血脂异常是心血管疾病 (CVD) 和慢性肾脏病 (CKD) 的与年龄相关的风险因素,但衰老本身就是一个独立的风险因素。随着年龄的增长,心脏和肾脏会逐渐但显著地发生炎症和随后的纤维化,最终导致器官生理功能不可逆转的下降。通过心脏-肾脏网络相互作用,心脏功能障碍导致肾脏损伤并对其作出反应,两者都促进了衰老的影响。因此,需要采用一种综合策略来评估心脏-肾脏衰老网络。跨系统共有的常见特征包括细胞外基质 (ECM) 积累,以及包括 MMP-9 在内的基质金属蛋白酶 (MMPs) 的上调。MMP-9 的广泛底物包括 ECM 成分和炎症细胞因子,这表明 MMP-9 参与了多种病理和与年龄相关的过程。有强有力的证据表明,炎症细胞来源的 MMP-9 会加重心脏-肾脏衰老。本综述探讨了针对老年人心血管疾病和慢性肾脏病的潜在治疗靶点,重点关注 ECM 和 MMP 的作用。